Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

TRUST me, I’m not a doctor. But as the first national newspaper journalist to investigate fat jabs, (and, in so doing, vomit ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Former child star Amanda Bynes has highlighted the toxic and invasive Hollywood culture and media, stating that she has started to use Ozempic for weight loss to “look better” in paparazzi pictures.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

By Sukriti Gupta and Sanchayaita Roy (Reuters) -European shares surged on Tuesday as investors' risk appetite improved after ...

Scientists created a new weight-loss drug that protects blood sugar levels and muscle mass. The new weight-loss tablet was ...

FAT jabs are shrinking supermarket sales, with grocery volumes falling 0.4% year-on-year, new figures reveal. Popular Ozempic ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and ...